Mucosis appoints Thomas Johnston as Chief Business Officer

Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. today announced the appoint­ment of Thomas Johnston as Chief Business Officer. In this role he will have glob­al respon­si­bil­i­ty for the licens­ing and mar­ket­ing of Mucosis’s tech­nolo­gies, nego­ti­at­ing cor­po­rate part­ner­ships and oth­er strate­gic alliances.

Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-list­ed clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny. As Vice President of Strategy he devel­oped and exe­cut­ed a region­al part­ner­ship strat­e­gy with deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an exec­u­tive-lev­el strate­gic con­sul­tant in a num­ber of indus­tries includ­ing biotech, and held var­i­ous senior-lev­el posi­tions with a num­ber of world-class orga­ni­za­tions such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
“Tom has more than 15 years of busi­ness devel­op­ment expe­ri­ence and an in-depth under­stand­ing of the vac­cine and biotech­nol­o­gy space. Therefore we are very pleased to wel­come him to our team.” said Govert Schouten, Chief Executive Officer of Mucosis. “Through this appoint­ment, we extend our busi­ness devel­op­ment reach for the suc­cess of our Mimopath™-based vac­cine can­di­dates.”

Tom Johnston added: “I am excit­ed to join the Mucosis man­age­ment team. The com­pa­ny has made great progress to date and is now ready to move to broad­en­ing mar­ket aware­ness of its tech­nol­o­gy plat­form and vac­cine pipeline.”

Leave a Reply

Your email address will not be published. Required fields are marked *